Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Big in biotech: three managers you should know about

Citywire Switzerland takes a closer look at the three top performing managers in the biotech sector.

As investors in the biotechnology sector keep a close watch on the Trump administration’s policy movements in the US and the M&A activity in the wider industry, we take a look at the fund managers dominating the sector.

Since the beginning of the year, despite an upward trend in stocks, the biotech sector has had negative net flows of CHF 77.40 million, with just three funds attracting positive flows.

The average manager’s total return in the biotech sector over three years to the end of July 2017 was 35.7%.

Let’s take a look at the high-flying managers who are generating the top returns and attracting the most money.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

3.Rudi Van den Eynde, Candriam

Fund managed:Candriam Equities L Biotechnology C Cap

Total return over three years: 42.6%

Rudi Van den Eynde is outperforming in the biotech sector, with strong returns on his Candriam biotech.

The Citywire A rated manager has managed the $750.17 million fund since its launch in 2000.

The Candriam fund has received the highest net flows in the sector since the beginning of the year, totaling CHF 62.27 million.

In his July 2017 monthly fund comment, Van den Eynde said that after a strong month in June, some consolidation is to be expected, with July leaving a ‘sense of frustration in spite of stunning earnings releases.’

The Candriam Equities L Biotechnology fund has returned 42.6% over three years to the end of 2017, compared with a return of 31.59% from its benchmark, LCI NASDAQ Biotech/MSCI World Health Care (50:50), over the same period.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

2.Ivo Staijen, HBM Partners

Fund managed:HBM Global Biotechnology Fund -USD-

Total return over three years: 46.0%

Ranking second over three years, Citywire AA rated Ivo Staijen is the sector leader and comes in first place over five years, with a total return of 173.0%.

Staijen took on responsibility for the HBM Global Biotechnology Fund in January 2012 shortly after its official launch.

He has more than four years’ experience in the pharma industry and 14 years of portfolio management and investment analysis experience in the healthcare sector.

The US$34.4 million HBM biotech fund is largely invested in North America, which accounts for 90% of the portfolio, with the remaining 10% in Europe.

The fund currently outperforms its benchmark, the MSCI World/Biotechnology TR, which returned 37.11% over three years to the end of July 2017.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

1.David Pinniger, Polar Capital

Fund managed: Polar Capital Biotechnology R USD

Total return over three years: 67.8%

In first place and leading the way in the biotech sector is Citywire AAA rated David Pinniger on the Polar Capital Biotechnology fund.

Pinniger has managed the fund since its launch. He joined Polar Capital in 2013 and has 17 years of industry experience.

The $206.3 million biotech fund is predominantly invested in the US, which accounts for 72.8% of the portfolio. Denmark and the UK are the next largest country exposures, making up 5.3% and 5.2% of the fund respectively.

The fund attracted the second highest net flows in the sector since the beginning of the year, beaten only by the Candriam fund, with net flows of CHF 59.26 million.

Over three years to the end of July 2017, the Polar Capital Biotechnology fund generated a total return of 67.8%, almost doubling the benchmark, the NASDAQ Biotechnology TR, which returned 36.56% over the same period.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

Related Fund Managers

Rudi Van den Eynde
Rudi Van den Eynde
2/9 in Equity - Biotechnology (Performance over 3 years) Average Total Return: 35.66%
David Pinniger
David Pinniger
1/9 in Equity - Biotechnology (Performance over 3 years) Average Total Return: 56.66%
Ivo Staijen
Ivo Staijen
Events
  • Citywire DACH 2016

    Citywire DACH 2016

  • Citywire Switzerland 2016

    Citywire Switzerland 2016

  • Citywire Zurich Alt Ucits 2016

    Citywire Zurich Alt Ucits 2016

  • Citywire Zurich Alt Ucits 2016

    Citywire Zurich Alt Ucits 2016

  • Citywire Zurich Alt Ucits 2016

    Citywire Zurich Alt Ucits 2016

  • Citywire Montreux 2016

    Citywire Montreux 2016

  • Citywire Montreux 2016

    Citywire Montreux 2016

  • Citywire Montreux 2016

    Citywire Montreux 2016

  • Citywire Zurich 2016

    Citywire Zurich 2016

  • Citywire Zurich 2016

    Citywire Zurich 2016

  • Citywire Zurich 2016

    Citywire Zurich 2016

  • Citywire Switzerland 2015, Gstaad

    Citywire Switzerland 2015, Gstaad

  • Zurich Forum 2015

    Zurich Forum 2015

  • Zurich Forum 2015

    Zurich Forum 2015

  • Geneva Roundtable 2015

    Geneva Roundtable 2015

  • Geneva Forum 2015

    Geneva Forum 2015

  • Geneva Forum 2015

    Geneva Forum 2015

  • Citywire Gstaad 2014

    Citywire Gstaad 2014